Anwen Xiong - Department of Medical OncologyShanghai Pulmonary HospitalTongji University School of MedicineShanghaiChina

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 52 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Camrelizumab Plus Nab-Paclitaxel and Carboplatin As First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial

Jia Yu,Anwen Xiong,Lei Wang,Xinlong Zheng,Tao Jiang,Qi Wang,Bin Chen,Menghang Yang,Wei Li, Jiajia Yuan, Changhong Zhao,Xiaohui Chen,Caicun Zhou,Shengxiang Ren

crossref（2024）

引用0浏览0引用

CXCR1+ Neutrophil Infiltration Orchestrates Response to Third-Generation EGFR-TKI in EGFR Mutant Non-Small-cell Lung Cancer

Haowei Wang,Anwen Xiong,Xiaoxia Chen,Junhong Guo, Zhuoran Tang,Chunyan Wu,Shengxiang Ren,Caicun Zhou, Jian Chen,Likun Hou,Tao Jiang

Signal Transduction and Targeted Therapyno. 1 (2024): 1-15

引用0浏览0WOSNATURE引用

Evaluating Efficacy and Safety of a Novel Registration-Free CT-guided Needle Biopsy Navigation System (RC 120): A Multicenter, Prospective Clinical Trial

Lei Wang,Biao Song, Zheng Zhang,Bing Bo,Anwen Xiong, Lingyun Ye, Dacheng Xie, Juanjuan Li,Sha Zhao, Chenlei Cai,Shanghu Wang,Yuan Li,Qilong Song, Zhaohua Wang, Mengjie Wang, Yanan Cao, Hui Yin, Kunpeng Ji, Chunfu Fang, Shu-ting Shen

Lung cancer (Amsterdam, Netherlands) (2024): 108025-108025

引用0浏览0WOS引用

Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: the Phase II TRUST-I Study

Wei Li,Anwen Xiong,Nong Yang,Huijie Fan,Qitao Yu,Yanqiu Zhao,Yongsheng Wang,Xue Meng,Jingxun Wu,Ziping Wang,Yunpeng Liu,Xicheng Wang,Xintian Qin,Kaihua Lu,Wu Zhuang, Yizhong Ren, Xianyu Zhang, Bing Yan,Christine M. Lovly,Caicun Zhou

Journal of Clinical Oncologyno. 22 (2024): 2660-2670

引用0浏览0WOS引用

Prognostic Role of Dynamic Changes in Inflammatory Indicators in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors—a Retrospective Cohort Study

Liang Guo,Juanjuan Li,Jing Wang,Xinru Chen,Chenlei Cai, Fei Zhou,Anwen Xiong

TRANSLATIONAL LUNG CANCER RESEARCHno. 8 (2024): 1975-1987

引用0浏览0WOS引用

SLC40A1+ Macrophages Contribute to the Immunosuppressive Tumor Microenvironment in EGFR-mutated Lung Cancer

Xinyu Song, Zongjuan Li, Xuanhe Wang, He Du, Yijun Jia, Shen Chen,Anwen Xiong,Wei Li,Xuefei Li,Lei Cheng, Chao Zhao,Lei Wang, Guanghui Gao,Xiaoxia Chen, Chunyan Wu, Zhikai Zhao,Shengxiang Ren,Caicun Zhou,Fengying Wu

Science bulletin (2024)

引用0浏览0WOS引用

Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1+ Non–small Cell Lung Cancer: the Phase 2 TRUST-I Study

Journal of Clinical Oncologyno. 16_suppl (2024): 8520-8520

引用0浏览0引用

Camrelizumab Plus Famitinib in Previously Chemo-Immunotherapy Treated Patients with Advanced NSCLC: Results from an Open-Label Multicenter Phase 2 Basket Study

Cancer Immunology Immunotherapyno. 7 (2024)

引用0浏览0WOS引用

First-in-human, Phase 1 Dose-Escalation and Dose-Expansion Study of a RET Inhibitor SY-5007 in Patients with Advanced RET-altered Solid Tumors

Wei Li,Yongsheng Wang,Anwen Xiong,Ge Gao,Zhengbo Song,Yiping Zhang,Dingzhi Huang,Feng Ye,Qiming Wang,Zhihui Li,Jiaye Liu,Chunwei Xu, Yinghui Sun, Xijie Liu, Fei Zhou,Caicun Zhou

SIGNAL TRANSDUCTION AND TARGETED THERAPYno. 1 (2024)

引用0浏览0WOSNATURE引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn